Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Network Pharmacology Identifies Stigmasterol as an Anti-Gastric Cancer Agent Targeting HSP90AA1 for Ubiquitin-Mediated Degradation.

Created on 04 Nov 2026

Authors

Haifeng Zhang, Yihong Zhang, Yanxuan Ling, Guangqing Jiang, Junjie Wu, Xin Shi, Yupeng Zhao

Published in

Journal of visualized experiments : JoVE. Issue 237. Nov 03, 2026. Epub Nov 03, 2026.

Abstract

Gastric cancer (GC) remains a major cause of cancer mortality. We combined network pharmacology, molecular docking, molecular dynamics simulations, public database analyses, and cell-based assays to investigate stigmasterol and heat shock protein 90 alpha family class A member 1 (HSP90AA1). Computational screening prioritized HSP90AA1 as a candidate target. In AGS and MKN-45 cells, stigmasterol treatment reduced cell viability and DNA synthesis, increased the proportion of Annexin V-positive cells, and decreased HSP90AA1 protein abundance. No statistically significant change in HSP90AA1 mRNA abundance was detected under the conditions tested. Increased ubiquitin signal in HSP90AA1 immunoprecipitates and attenuation of protein loss by MG-132 were consistent with proteasome involvement. Public database analyses showed higher HSP90AA1 expression in GC tissues and an association with clinical stage. These findings link stigmasterol treatment to HSP90AA1 downregulation in GC cells. Direct binding, the contribution of HSP90AA1 loss to the cellular effects, and in vivo efficacy remain to be established.

PMID:
42980202
Bibliographic data and abstract were imported from PubMed on 04 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 14
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement